Disease spectrum of abnormal serum free light chain ratio and its diagnostic significance

15Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

Objective: To analyze the spectrum of abnormal serum free light chain ratio (sFLC κ/λ ratio), and to redefine the range of sFLC κ/λ ratio, so as to achieve hierarchical diagnosis of diseases with abnormal sFLC κ/λ ratio, resulting in the increased sensitivity and specificity in the diagnosis of monoclonal plasma diseases. Methods: Enrolled 1,340 patients with abnormal sFLC κ/λ ratio ( < 0.26 or > 1.65) were grouped: (1) group A: malignant plasma diseases; (2) group B: monoclonal gammopathies of undetermined significance (MGUS); (3) group C: reactive plasma diseases. These patients were further divided by renal function eGFR < 60 or > 60 ml/min/1.73m2 to eliminate renal diseases influencing the results. Statistical analyses was performed by using SPSS 22 software. Results: When sFLC κ/λ ratio > 3.49 and eGFR > 60ml/min/1.73m2, the sensitivity and specificity of the diagnosis of malignant plasma diseases were 86.1% and 94.0%, respectively. When sFLC κ/λ ratio > 2.89 and eGFR < 60ml/min/1.73m2, the sensitivity and specificity of the diagnosis of malignant plasma diseases were 92.0% and 97.0%, respectively. Conclusion: The sensitivity and specificity of the diagnosis of monoclonal plasma diseases can be significantly improved by redefining the cut-off value of sFLC κ/λ ratio and the renal function index of eGFR.

Cite

CITATION STYLE

APA

Xu, B., Tang, Y., Zhou, J., Zhang, P., & Li, H. (2017). Disease spectrum of abnormal serum free light chain ratio and its diagnostic significance. Oncotarget, 8(47), 82268–82279. https://doi.org/10.18632/oncotarget.19391

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free